WASHINGTON, DC – The House of Representatives today unanimously passed H.R. 4374, legislation accompanying the National Defense Authorization Act (NDAA) Conference Report by voice vote. The NDAA Conference Report passed the House yesterday by a vote of 356-70.
H.R. 4374 will amend the Federal Food, Drug, and Cosmetic Act to authorize additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war, and for other purposes. Specifically, it addresses language within the NDAA that would undermine the U.S. Food and Drug Administration (FDA).
“Our brave men and women in uniform deserve the best care possible, especially timely treatments while they put their lives on the line,” said Energy and Commerce Committee Chairman Greg Walden (R-OR) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX). “H.R. 4374 addresses a provision that could usurp FDA’s vital authority and long-standing process in reviewing and delivering cutting edge medicines and devices. It is critical this bill continue to move alongside the NDAA as it heads over to the Senate for final consideration, so we can continue to deliver the newest treatments and devices to our war fighters without forgoing important safety mechanisms.”